Pro Medicus Ltd
ASX:PME

Watchlist Manager
Pro Medicus Ltd Logo
Pro Medicus Ltd
ASX:PME
Watchlist
Price: 249 AUD -1.12% Market Closed
Market Cap: 26B AUD

Pro Medicus Ltd
Net Change in Cash

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Pro Medicus Ltd
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Pro Medicus Ltd
ASX:PME
Net Change in Cash
AU$47.4m
CAGR 3-Years
30%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Mach7 Technologies Ltd
ASX:M7T
Net Change in Cash
-AU$1.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
4DMedical Ltd
ASX:4DX
Net Change in Cash
AU$15.2m
CAGR 3-Years
N/A
CAGR 5-Years
23%
CAGR 10-Years
N/A
CogState Ltd
ASX:CGS
Net Change in Cash
$5.4m
CAGR 3-Years
-8%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Alcidion Group Ltd
ASX:ALC
Net Change in Cash
AU$5.9m
CAGR 3-Years
N/A
CAGR 5-Years
-14%
CAGR 10-Years
N/A
A
Artrya Ltd
ASX:AYA
Net Change in Cash
AU$4.2m
CAGR 3-Years
22%
CAGR 5-Years
26%
CAGR 10-Years
N/A
No Stocks Found

Pro Medicus Ltd
Glance View

Pro Medicus Ltd, an Australian company founded in 1983, has etched its name in the field of healthcare IT, primarily through its innovative medical imaging software solutions. The brainchild of Dr. Sam Hupert and Anthony Hall, the company originally sought to provide radiology practices with digital solutions for image management and viewing. Over the years, Pro Medicus has meticulously evolved its offerings to become a leader in picture archiving and communication systems (PACS), radiology information systems (RIS), and an expanding range of e-health solutions. Its flagship product, Visage 7, is renowned for delivering fast and sophisticated viewing capabilities, enabling radiologists to efficiently interpret complex imaging data. Under its hood, the company’s technology is powered by advanced streaming capabilities, allowing for large files to be quickly accessed and reviewed, essential for high-demand environments. The monetization model of Pro Medicus largely revolves around licensing agreements for its software, alongside service and support fees, ensuring a steady and recurring revenue stream. The company has successfully leveraged its expertise to penetrate key markets, notably the United States and Europe, where it partners with some of the most prestigious hospitals and research institutions. By focusing on high-end offerings and fostering long-term client relationships, Pro Medicus has cemented a premium positioning in the healthcare IT landscape. The strategic focus on innovation, coupled with a keen understanding of the evolving needs of healthcare providers, allows Pro Medicus to continually refine its services, ensuring it remains at the forefront of technological advancements that ultimately enhance diagnostic efficiency and patient outcomes.

PME Intrinsic Value
HIDDEN
Show

See Also

What is Pro Medicus Ltd's Net Change in Cash?
Net Change in Cash
47.4m AUD

Based on the financial report for Jun 30, 2025, Pro Medicus Ltd's Net Change in Cash amounts to 47.4m AUD.

What is Pro Medicus Ltd's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
34%

The average annual Net Change in Cash growth rates for Pro Medicus Ltd have been 30% over the past three years , 34% over the past five years .

Back to Top